본문으로 건너뛰기
← 뒤로

Multiprobe PET Imaging: Insignia of Tumor Heterogeneity in a Case of Neuroendocrine Prostate Cancer.

1/5 보강
Clinical nuclear medicine 📖 저널 OA 3.9% 2021: 0/2 OA 2022: 1/12 OA 2023: 0/8 OA 2024: 0/22 OA 2025: 3/79 OA 2026: 5/104 OA 2021~2026 2026 Vol.51(3) p. e159-e162
Retraction 확인
출처

Bedmutha A, Barron B, Lau S, Oi K, Brandon D

📝 환자 설명용 한 줄

Neuroendocrine prostate cancer (NEPC) is an aggressive subtype of prostate cancer, often developing from androgen receptor (AR) independence, characterized by neuroendocrine molecular markers and nonr

이 논문을 인용하기

↓ .bib ↓ .ris
APA Bedmutha A, Barron B, et al. (2026). Multiprobe PET Imaging: Insignia of Tumor Heterogeneity in a Case of Neuroendocrine Prostate Cancer.. Clinical nuclear medicine, 51(3), e159-e162. https://doi.org/10.1097/RLU.0000000000006182
MLA Bedmutha A, et al.. "Multiprobe PET Imaging: Insignia of Tumor Heterogeneity in a Case of Neuroendocrine Prostate Cancer.." Clinical nuclear medicine, vol. 51, no. 3, 2026, pp. e159-e162.
PMID 41283778 ↗

Abstract

Neuroendocrine prostate cancer (NEPC) is an aggressive subtype of prostate cancer, often developing from androgen receptor (AR) independence, characterized by neuroendocrine molecular markers and nonresponsiveness to standard treatments of prostate adenocarcinoma. The evolution of adenocarcinoma to NEPC is characterized by epigenetic changes, leading to the downregulation of the PSMA transmembrane protein, as well as the upregulation of FDG-uptake pathways and somatostatin receptor expression. We present a case of NEPC that depicts a significant metastatic intertumoral heterogeneity as depicted on PSMA, FDG, and DOTATATE PET/CT scans. Such multiprobe PET evaluation of NEPC may assist in sampling the most aggressive disease and guide an appropriate management strategy. It also provides a cellular-level insight into this dreadful disease with very limited treatment options.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반